JPWO2022043900A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022043900A5 JPWO2022043900A5 JP2023513278A JP2023513278A JPWO2022043900A5 JP WO2022043900 A5 JPWO2022043900 A5 JP WO2022043900A5 JP 2023513278 A JP2023513278 A JP 2023513278A JP 2023513278 A JP2023513278 A JP 2023513278A JP WO2022043900 A5 JPWO2022043900 A5 JP WO2022043900A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- amino acid
- stable aqueous
- aqueous pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 57
- 150000001413 amino acids Chemical group 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 20
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 14
- 229960002885 histidine Drugs 0.000 claims description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 12
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 12
- 229920000053 polysorbate 80 Polymers 0.000 claims description 12
- 229940068968 polysorbate 80 Drugs 0.000 claims description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 10
- 102000001301 EGF receptor Human genes 0.000 claims description 10
- 108060006698 EGF receptor Proteins 0.000 claims description 10
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 10
- 150000002411 histidines Chemical class 0.000 claims description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229960004452 methionine Drugs 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 229940008421 amivantamab Drugs 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 4
- 239000013628 high molecular weight specie Substances 0.000 claims description 4
- 239000013627 low molecular weight specie Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 3
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 2
- 229930195722 L-methionine Natural products 0.000 claims description 2
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims description 2
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000012906 subvisible particle Substances 0.000 claims description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070440P | 2020-08-26 | 2020-08-26 | |
| US63/070,440 | 2020-08-26 | ||
| PCT/IB2021/057802 WO2022043900A1 (en) | 2020-08-26 | 2021-08-26 | Stable formulations comprising a bispecific egfr/c-met antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540025A JP2023540025A (ja) | 2023-09-21 |
| JPWO2022043900A5 true JPWO2022043900A5 (enrdf_load_stackoverflow) | 2024-09-02 |
Family
ID=80352835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513278A Pending JP2023540025A (ja) | 2020-08-26 | 2021-08-26 | 二重特異性ｅｇｆｒ／ｃ－ｍｅｔ抗体を含む安定な製剤 |
Country Status (16)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202308689A (zh) * | 2021-04-21 | 2023-03-01 | 美商健生生物科技公司 | 高濃度的雙特異性抗體調配物 |
| CN119790073A (zh) | 2022-06-30 | 2025-04-08 | 詹森生物科技公司 | 使用抗EGFR/抗Met抗体治疗胃癌或食道癌 |
| WO2025011471A1 (en) * | 2023-07-07 | 2025-01-16 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Egfr/c-met bispecific binding protein and use thereof |
| WO2025079020A1 (en) | 2023-10-12 | 2025-04-17 | Janssen Biotech, Inc. | First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100989280B1 (ko) * | 2005-03-08 | 2010-10-20 | 파마시아 앤드 업존 캄파니 엘엘씨 | 항-ｃｔｌａ-4 항체 조성물 |
| LT2922872T (lt) * | 2012-11-21 | 2018-12-27 | Janssen Biotech, Inc. | Bispecifiniai egfr/c-met antikūnai |
| TW202308689A (zh) * | 2021-04-21 | 2023-03-01 | 美商健生生物科技公司 | 高濃度的雙特異性抗體調配物 |
-
2021
- 2021-08-24 TW TW110131219A patent/TW202227129A/zh unknown
- 2021-08-24 AR ARP210102390A patent/AR123340A1/es unknown
- 2021-08-26 CA CA3192630A patent/CA3192630A1/en active Pending
- 2021-08-26 AU AU2021333882A patent/AU2021333882A1/en active Pending
- 2021-08-26 PE PE2023000717A patent/PE20231370A1/es unknown
- 2021-08-26 MX MX2023002367A patent/MX2023002367A/es unknown
- 2021-08-26 CN CN202180052293.6A patent/CN116194485A/zh active Pending
- 2021-08-26 US US17/412,346 patent/US20220064307A1/en active Pending
- 2021-08-26 IL IL300895A patent/IL300895A/en unknown
- 2021-08-26 EP EP21860689.5A patent/EP4204456A4/en active Pending
- 2021-08-26 CR CR20230102A patent/CR20230102A/es unknown
- 2021-08-26 KR KR1020237009728A patent/KR20230057400A/ko active Pending
- 2021-08-26 JP JP2023513278A patent/JP2023540025A/ja active Pending
- 2021-08-26 BR BR112023003373A patent/BR112023003373A2/pt unknown
- 2021-08-26 WO PCT/IB2021/057802 patent/WO2022043900A1/en active Application Filing
- 2021-11-15 AR ARP210103156A patent/AR124067A2/es unknown
-
2023
- 2023-02-24 EC ECSENADI202313655A patent/ECSP23013655A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3479819B1 (en) | Stable liquid pharmaceutical preparation | |
| IL280087A (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| FI4249512T3 (fi) | Stabiili vasta-aineformulaatio | |
| CN115666649B (zh) | 一种新型冠状病毒抗体的药物组合物及其用途 | |
| JP7551822B2 (ja) | 治療用抗体製剤 | |
| JP2022166006A (ja) | 液体医薬組成物 | |
| KR20160105535A (ko) | TNF-α 항체의 약제학적 제형 | |
| AU2007229554A1 (en) | Anti-IGF-1R human monoclonal antibody formulation | |
| MX2015002411A (es) | Formulaciones de anticuerpos y proteinas. | |
| WO2023011502A1 (zh) | 含有抗il-4r抗体的稳定制剂 | |
| CA3115708A1 (en) | Formulations of anti-rsv antibodies and methods of use thereof | |
| AR124067A2 (es) | Formulaciones estables que comprenden un anticuerpo biespecífico para egfr / c-met | |
| JP2022105056A (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 | |
| JP2023535433A (ja) | Ｐｄ－ｌ１／ｌａｇ－３二重特異性抗体製剤およびその調製方法ならびに使用 | |
| JP7502286B2 (ja) | 抗ｐｃｓｋ９抗体を含む安定製剤 | |
| RU2589691C2 (ru) | Стабильная композиция антитела, специфически связывающегося с her2 рецепторами, и способ ее получения | |
| RU2020111574A (ru) | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом | |
| JPWO2022043900A5 (enrdf_load_stackoverflow) | ||
| JPWO2022224187A5 (enrdf_load_stackoverflow) | ||
| CN118105485B (zh) | 一种稳定的抗人IL-4Rα单克隆抗体制剂 | |
| JPWO2022231978A5 (enrdf_load_stackoverflow) | ||
| CN114867468A (zh) | 尼妥珠单抗的稳定和高浓度制剂 | |
| HK40069022A (en) | Stable and highly concentrated formulation of the antibody nimotuzumab | |
| HK40085301A (en) | Stable pharmaceutical composition of novel coronavirus neutralizing antibody and use thereof | |
| TW202409078A (zh) | 穩定之包含抗gremlin1抗體的藥物製劑 |